Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia.
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Jul 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2017.
- 19 Jan 2012 Planned patient number is 25 as reported by ClinicalTrials.gov.